Cargando…

CRISPR-Cas, a Revolution in the Treatment and Study of ESKAPE Infections: Pre-Clinical Studies

One of the biggest threats we face globally is the emergence of antimicrobial-resistant (AMR) bacteria, which runs in parallel with the lack in the development of new antimicrobials. Among these AMR bacteria pathogens belonging to the ESKAPE group can be highlighted (Enterococcus spp., Staphylococcu...

Descripción completa

Detalles Bibliográficos
Autores principales: González de Aledo, Manuel, González-Bardanca, Mónica, Blasco, Lucía, Pacios, Olga, Bleriot, Inés, Fernández-García, Laura, Fernández-Quejo, Melisa, López, María, Bou, Germán, Tomás, María
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8300728/
https://www.ncbi.nlm.nih.gov/pubmed/34206474
http://dx.doi.org/10.3390/antibiotics10070756
_version_ 1783726517159723008
author González de Aledo, Manuel
González-Bardanca, Mónica
Blasco, Lucía
Pacios, Olga
Bleriot, Inés
Fernández-García, Laura
Fernández-Quejo, Melisa
López, María
Bou, Germán
Tomás, María
author_facet González de Aledo, Manuel
González-Bardanca, Mónica
Blasco, Lucía
Pacios, Olga
Bleriot, Inés
Fernández-García, Laura
Fernández-Quejo, Melisa
López, María
Bou, Germán
Tomás, María
author_sort González de Aledo, Manuel
collection PubMed
description One of the biggest threats we face globally is the emergence of antimicrobial-resistant (AMR) bacteria, which runs in parallel with the lack in the development of new antimicrobials. Among these AMR bacteria pathogens belonging to the ESKAPE group can be highlighted (Enterococcus spp., Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.) due to their profile of drug resistance and virulence. Therefore, innovative lines of treatment must be developed for these bacteria. In this review, we summarize the different strategies for the treatment and study of molecular mechanisms of AMR in the ESKAPE pathogens based on the clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins’ technologies: loss of plasmid or cellular viability, random mutation or gene deletion as well directed mutations that lead to a gene’s loss of function.
format Online
Article
Text
id pubmed-8300728
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83007282021-07-24 CRISPR-Cas, a Revolution in the Treatment and Study of ESKAPE Infections: Pre-Clinical Studies González de Aledo, Manuel González-Bardanca, Mónica Blasco, Lucía Pacios, Olga Bleriot, Inés Fernández-García, Laura Fernández-Quejo, Melisa López, María Bou, Germán Tomás, María Antibiotics (Basel) Review One of the biggest threats we face globally is the emergence of antimicrobial-resistant (AMR) bacteria, which runs in parallel with the lack in the development of new antimicrobials. Among these AMR bacteria pathogens belonging to the ESKAPE group can be highlighted (Enterococcus spp., Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.) due to their profile of drug resistance and virulence. Therefore, innovative lines of treatment must be developed for these bacteria. In this review, we summarize the different strategies for the treatment and study of molecular mechanisms of AMR in the ESKAPE pathogens based on the clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins’ technologies: loss of plasmid or cellular viability, random mutation or gene deletion as well directed mutations that lead to a gene’s loss of function. MDPI 2021-06-22 /pmc/articles/PMC8300728/ /pubmed/34206474 http://dx.doi.org/10.3390/antibiotics10070756 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
González de Aledo, Manuel
González-Bardanca, Mónica
Blasco, Lucía
Pacios, Olga
Bleriot, Inés
Fernández-García, Laura
Fernández-Quejo, Melisa
López, María
Bou, Germán
Tomás, María
CRISPR-Cas, a Revolution in the Treatment and Study of ESKAPE Infections: Pre-Clinical Studies
title CRISPR-Cas, a Revolution in the Treatment and Study of ESKAPE Infections: Pre-Clinical Studies
title_full CRISPR-Cas, a Revolution in the Treatment and Study of ESKAPE Infections: Pre-Clinical Studies
title_fullStr CRISPR-Cas, a Revolution in the Treatment and Study of ESKAPE Infections: Pre-Clinical Studies
title_full_unstemmed CRISPR-Cas, a Revolution in the Treatment and Study of ESKAPE Infections: Pre-Clinical Studies
title_short CRISPR-Cas, a Revolution in the Treatment and Study of ESKAPE Infections: Pre-Clinical Studies
title_sort crispr-cas, a revolution in the treatment and study of eskape infections: pre-clinical studies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8300728/
https://www.ncbi.nlm.nih.gov/pubmed/34206474
http://dx.doi.org/10.3390/antibiotics10070756
work_keys_str_mv AT gonzalezdealedomanuel crisprcasarevolutioninthetreatmentandstudyofeskapeinfectionspreclinicalstudies
AT gonzalezbardancamonica crisprcasarevolutioninthetreatmentandstudyofeskapeinfectionspreclinicalstudies
AT blascolucia crisprcasarevolutioninthetreatmentandstudyofeskapeinfectionspreclinicalstudies
AT paciosolga crisprcasarevolutioninthetreatmentandstudyofeskapeinfectionspreclinicalstudies
AT bleriotines crisprcasarevolutioninthetreatmentandstudyofeskapeinfectionspreclinicalstudies
AT fernandezgarcialaura crisprcasarevolutioninthetreatmentandstudyofeskapeinfectionspreclinicalstudies
AT fernandezquejomelisa crisprcasarevolutioninthetreatmentandstudyofeskapeinfectionspreclinicalstudies
AT lopezmaria crisprcasarevolutioninthetreatmentandstudyofeskapeinfectionspreclinicalstudies
AT bougerman crisprcasarevolutioninthetreatmentandstudyofeskapeinfectionspreclinicalstudies
AT tomasmaria crisprcasarevolutioninthetreatmentandstudyofeskapeinfectionspreclinicalstudies